1. Search Result
Search Result
Results for "

CSF1

" in MedChemExpress (MCE) Product Catalog:

84

Inhibitors & Agonists

10

Inhibitory Antibodies

45

Recombinant Proteins

3

Antibodies

6

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-147615

    c-Fms Cancer
    CSF1R-IN-12 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-12 has the potential for the research of cancer diseases (extracted from patent WO2019134661A1, compound 1) [1].
    CSF1R-IN-12
  • HY-RS03227

    Small Interfering RNA (siRNA) Others

    CSF1 Human Pre-designed siRNA Set A contains three designed siRNAs for CSF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CSF1 Human Pre-designed siRNA Set A
    CSF1 Human Pre-designed siRNA Set A
  • HY-RS23294

    Small Interfering RNA (siRNA) Others
    Csf1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Csf1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Csf1 Rat Pre-designed siRNA Set A
    Csf1 Rat Pre-designed siRNA Set A
  • HY-RS16853

    Small Interfering RNA (siRNA)
    Csf1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Csf1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Csf1 Mouse Pre-designed siRNA Set A
    Csf1 Mouse Pre-designed siRNA Set A
  • HY-155001

    c-Fms Others
    CSF1R-IN-15 (compound 23) is an inhibitor targeting CSF1R. The colony-stimulating factor-1 receptor (CSF1R) is a tyrosine kinase embedded in the cell membrane of macrophages. The receptor is activated by colony-stimulating factor-1 (CSF-1) and interleukin-34, and signaling via CSF1R is crucial for the differentiation, proliferation, and survival of macrophages [1].
    CSF1R-IN-15
  • HY-147616

    c-Fms Cancer
    CSF1R-IN-13 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-13 has the potential for the research of cancer diseases (extracted from patent WO2019134661A1, compound 32) [1].
    CSF1R-IN-13
  • HY-147617

    c-Fms Cancer
    CSF1R-IN-14 is an isoindolinone derivative compound. CSF1R-IN-14 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-14 has the potential for the research of cancer diseases (extracted from patent WO2019134662A1, compound 1) [1].
    CSF1R-IN-14
  • HY-162309

    c-Fms Cancer
    CSF1R-IN-20 (compound 7a) is a CSF-1R Inhibitor with an IC50 value of 467 nM. CSF1R-IN-20 inhibits CSF-1R auto-phosphorylation [1].
    CSF1R-IN-20
  • HY-144041

    c-Fms Cancer
    CSF1R-IN-5 is a potent inhibitor of CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-5 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-5 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 11) [1].
    CSF1R-IN-5
  • HY-144040

    c-Fms Cancer
    CSF1R-IN-4 is a potent inhibitor of CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-4 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-4 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 104) [1].
    CSF1R-IN-4
  • HY-144042

    c-Fms Cancer
    CSF1R-IN-6 is a potent inhibitor of CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-6 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-6 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 5) [1].
    CSF1R-IN-6
  • HY-157996

    c-Fms Neurological Disease
    CSF1R-IN-21 (compound 7e) is a CSF-1R Inhibitor with an IC50 value of 31 nM. CSF1R-IN-21 inhibits CSF-1R auto-phosphorylation and can be used for the research of neurodegenerative diseases [1].
    CSF1R-IN-21
  • HY-147608

    c-Fms Neurological Disease
    CSF1R-IN-7 (Formula I) is a CSF-1R inhibitor. CSF1R-IN-7 can be used for Alzheimer’s disease research [1].
    CSF1R-IN-7
  • HY-157422

    c-Fms Cancer
    CSF1R-IN-19 is a potent inhibitor of CSF1R. CSF1R-IN-19 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-19 has the potential for the research of cancer [1].
    CSF1R-IN-19
  • HY-147610

    c-Fms Cancer
    CSF1R-IN-9 (Compound 46) is a CSF-1R inhibitor with an IC50 of 0.028 μM [1].
    CSF1R-IN-9
  • HY-147609

    c-Fms Cancer
    CSF1R-IN-8 (Compound 22) is a CSF-1R inhibitor with an IC50 of 0.012 μM [1].
    CSF1R-IN-8
  • HY-147611

    c-Fms Cancer
    CSF1R-IN-10 (Compound 48) is a CSF-1R inhibitor with an IC50 of 0.005 μM [1].
    CSF1R-IN-10
  • HY-158363

    c-Fms Neurological Disease Inflammation/Immunology Cancer
    CSF1R-IN-25 (compound 36) is an orally effective CSF1R inhibitor. CSF1R-IN-25 can be used to study cancer, inflammation, and neurodegeneration [1].
    CSF1R-IN-25
  • HY-155550

    c-Fms Inflammation/Immunology
    CSF1R-IN-17 (compound 9) is a potent and selective CSF1R antagonist, with an IC50 of 0.2 nM. CSF1R-IN-17 can inhibit osteoclast differentiation [1].
    CSF1R-IN-17
  • HY-158148

    c-Fms Neurological Disease Inflammation/Immunology
    CSF1R-IN-23 (Compound 7dri) is a selective inhibitor for colony-stimulating factor-1 receptor (CSF1R), with IC50 of 36.1 nM. CSF1R-IN-23 serves as antineuroinflammatory agent in mouse model. CSF1R-IN-23 is blood brain barrier (BBB) permeable [1].
    CSF1R-IN-23
  • HY-160842

    c-Fms Neurological Disease
    CSF1R-IN-24 (Example 134) is an orally active CSF1R inhibitor. CSF1R-IN-24 significantly inhibits the survival of human ipSC-derived microglia (hiPSC-MG) [1].
    CSF1R-IN-24
  • HY-168954

    c-Fms Apoptosis Akt ERK STAT Inflammation/Immunology Cancer
    CSF1R-IN-26 (Compound III-1) is the inhibitor for CSF-1R with an IC50 of 20.07 nM. CSF1R-IN-26 promotes the polarization of M2 macrophages to M1 macrophages, thereby inducing apoptosis in MC-38 cancer cell. CSF1R-IN-26 inhibits the activation of AKT/ERK/STAT3 signaling pathway. CSF1R-IN-26 reconstructs the tumor immune microenvironment and exhibits antitumor activity in mouse models. CSF1R-IN-26 exhibits pharmacokinetics characteristics in SD rats with a half-life 1.86 hours, and an oral bioavailability of 79.22% [1].
    CSF1R-IN-26
  • HY-101774
    CSF1R-IN-1
    1 Publications Verification

    c-Fms Cancer
    CSF1R-IN-1 is a CSF1R inhibitor with an with an IC50 of 0.5 nM.
    CSF1R-IN-1
  • HY-139990

    c-Fms Cancer
    CSF1R-IN-3 (compound 21) is a potent and orally active CSF-1R inhibitor (IC50=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells. CSF1R-IN-3 inhibits the progression of colorectal cancer by suppressing the migration of macrophages, reprograming M2-like macrophages to the M1 phenotype, and enhancing the antitumor immunity [1].
    CSF1R-IN-3
  • HY-161084

    c-Fms Neurological Disease Cancer
    CSF1R-IN-18 (Compdound 16t), para-aniline derivative, is a colony-stimulating factor 1 receptor (CSF1R) inhibitor. CSF1R-IN-18 can be used for the research of cancers, CNS-diseases and bone diseases [1].
    CSF1R-IN-18
  • HY-162415

    c-Fms Apoptosis Cancer
    CSF1R-IN-22 (Compound C19) is an orally effective CSF-1R selective inhibitor (IC50<6 nM). CSF1R-IN-22 enhances the secretion of CXCL9 from M2 macrophages, increases CD8 + T cell infiltration. CSF1R-IN-22 boosts anti-tumor immune responses of anti-PD-1, and induces apoptosis in tumor cells. CSF1R-IN-22 can effectively reprogram M2-like TAMs (tumor-associated macrophages) to the M1 phenotype and reshape the TME by inducing the recruitment of CD8 + T cells into tumors and reducing the infiltration of immunosuppressive Tregs and MDSCs [1].
    CSF1R-IN-22
  • HY-RS03228

    Small Interfering RNA (siRNA) Others

    CSF1R Human Pre-designed siRNA Set A contains three designed siRNAs for CSF1R gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CSF1R Human Pre-designed siRNA Set A
    CSF1R Human Pre-designed siRNA Set A
  • HY-RS03229

    Small Interfering RNA (siRNA) Others

    Csf1r Mouse Pre-designed siRNA Set A contains three designed siRNAs for Csf1r gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Csf1r Mouse Pre-designed siRNA Set A
    Csf1r Mouse Pre-designed siRNA Set A
  • HY-RS03230

    Small Interfering RNA (siRNA) Others

    Csf1r Rat Pre-designed siRNA Set A contains three designed siRNAs for Csf1r gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Csf1r Rat Pre-designed siRNA Set A
    Csf1r Rat Pre-designed siRNA Set A
  • HY-111787

    TPX-0022; CSF1R-IN-2

    Src c-Met/HGFR c-Fms Cancer
    Elzovantinib (TPX-0022) is an oral-active inhibitor of SRC, MET and c-FMS, with IC50 values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively [1].
    Elzovantinib
  • HY-P991048

    c-Fms Cancer
    AMG-820 is a fully human IgG2 antibody that targets CSF-1R. AMG-820 inhibits binding of the ligands CSF1 and IL34 and subsequent ligand-induced receptor activation. The isotype control for AMG-820 can refer to Human IgG2 kappa, Isotype Control (HY-P99002) [1].
    AMG-820
  • HY-P99368

    MCS110

    c-Fms Metabolic Disease Cancer
    Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis [1] .
    Lacnotuzumab
  • HY-112451

    c-Fms Inflammation/Immunology
    cFMS Receptor Inhibitor II is a CSF1R kinase inhibitor. CSF-1 is a cytokine [1].
    cFMS Receptor Inhibitor II
  • HY-112446

    Others Inflammation/Immunology
    ST638 is a potent tyrosine kinase inhibitor (IC50=370 nM). ST638 also targets the CSF-1 receptor and inhibits PGE2 production [1] .
    ST638
  • HY-145809

    Fatty Acid Synthase (FASN) Metabolic Disease Inflammation/Immunology Cancer
    FASN-IN-5 (example 11), a FASN inhibitor, can be used for the research of TH17- or CSF1 -mediated disease or disorder such as cancer, immunological disorders, and obesity [1].
    FASN-IN-5
  • HY-12768B

    BLZ945 dihydrochloride

    c-Fms Neurological Disease Cancer
    Sotuletinib (BLZ945) dihydrochloride is an orally active and blood-brain barrier-permeable CSF1-R-specific inhibitor (IC50=1 nM). Sotuletinib (BLZ945) dihydrochloride induces tumor cell apoptosis and effectively inhibits tumor growth in mouse models. Sotuletinib dihydrochloride can be used in cancer and amyotrophic lateral sclerosis (ALS) research [1].
    Sotuletinib dihydrochloride
  • HY-153277

    TAM Receptor c-Fms Neurological Disease
    Axl/Mer/CSF1R-IN-2 (Comp 4) is a Axl, Mer and CSF1R inhibitor [1].
    Axl/Mer/CSF1R-IN-2
  • HY-P990125

    c-Fms Others
    Anti-Mouse CSF1R (CD115) Antibody (AFS98) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CSF1R.
    Anti-Mouse (CSF1R/CD115) Antibody (AFS98)
  • HY-153012

    TAM Receptor c-Fms Cancer
    Axl/Mer-IN-1 (Compound 1) is an Axl/Mer receptor tyrosine kinase (Axl/Mer RTK) and CSF1R inhibitor with Kds of <0.1 μM [1].
    Axl/Mer/CSF1R-IN-1
  • HY-P99245

    RG 7155; RO 5509554

    c-Fms Cancer
    Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with Ki value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) [1] .
    Emactuzumab
  • HY-P99259

    FPA 008; Anti-Human CSF1R Recombinant Antibody

    c-Fms Inflammation/Immunology Cancer
    Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research [1] .
    Cabiralizumab
  • HY-117244
    AZD7507
    1 Publications Verification

    c-Fms Cancer
    AZD7507 is a potent and orally active CSF-1R inhibitor, with antitumor activity.
    AZD7507
  • HY-159503A

    3D185; HH185

    FGFR c-Fms Cancer
    Segigratinib hydrochloride (3D185) is a potent inhibitor of FGFR1/2/3 and CSF-1R; The IC50 values for FGFR1, FGFR2, FGFR3 and CSF-1R are 0.5, 1.3, 3.6 and 3.8 nM, respectively. Segigratinib hydrochloride has antitumor activity [1].
    Segigratinib hydrochloride
  • HY-P990043

    Ser/Thr Kinase TREM receptor Inflammation/Immunology
    Iluzanebart is a human monoclonal IgG1 antibody and is the agonist antibody for human TREM2 (hTREM2). Iluzanebart improves the survival and function of microglia by activating the TREM2 signaling pathway to compensate for the loss of CSF1R function. Iluzanebart can be used for research of adult-onset leukoencephalopathy associated with CSF1R (colony stimulating factor 1 receptor) (CSF1R-ALSP) [1].
    Iluzanebart
  • HY-101526

    RA03546849

    c-Fms Inflammation/Immunology
    GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor extracted from patent WO 2017015267A1.
    GENZ-882706
  • HY-122906

    c-Fms Inflammation/Immunology
    JTE-952 is a potent, oral active and selective Type II inhibitor of colony stimulating factor-1 receptor (CSF-1R or cFMS, type III receptor tyrosine kinase), with IC50 values of 13 nM and 261 nM for CSF1R and TrkA , respectively. Effective against a mouse collagen-induced model of arthritis [1].
    JTE-952
  • HY-119942

    c-Fms Cancer
    c-Fms-IN-8 (compound 4a) is a colony stimulating factor-1 receptor (CSF-1R, c-FMS) Type II inhibitor, with an IC50 of 9.1 nM [1].
    c-Fms-IN-8
  • HY-136362

    c-Fms Inflammation/Immunology Cancer
    ARRY-382 is a potent, oral and highly selective inhibitor of CSF1R/c-Fms with an IC50 of 9 nM. ARRY-382 can be used for the research of advanced or metastatic cancers [1].
    ARRY-382
  • HY-P99452

    SNDX-6352

    c-Fms Inflammation/Immunology Cancer
    Axatilimab (SNDX-6352) is a humanized IgG4 antibody with high affinity to CSF-1R. Axatilimab can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases [1] .
    Axatilimab
  • HY-159108

    c-Fms Cardiovascular Disease
    AZ683 is a potent and selective 3-amido-4-anilinoquinoline CSF1R inhibitor. AZ683 has high affinity for CSF1R (Ki=8 nM; IC50=6 nM). AZ683 has good oral bioavailability. [ 11C]AZ683 can be used as a positron emission tomography (PET) radiotracer for colony stimulating factor 1 receptor (CSF1R) [1] .
    AZ683

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: